Articles scientifiques

An update on PARP inhibitors-moving to the adjuvant setting.

Auteurs : Sonnenblick A, de Azambuja E, Azim HA, Piccart-Gebhart M
Année : 2015
Journal : Nat Rev Clin Oncol
Volume : 12(1)
Pages : 27-41

Erratum: Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study.

Auteurs : Hendlisz A, Golfinopoulos V, Deleporte A, Paesmans M, El Mansy H, Garcia C, Peeters M, Annemans L, Vandeputte C, Maetens M, Van den Eynde M, Maréchal R, Borbath I, Dresse D, Houbiers G, Fried M, Awada A, Piccart-Gebhart M, Van Laethem JL, Flamen P
Année : 2015
Journal : BMC Cancer
Volume : 15
Pages : 173

Will modern immunotherapies become the standard of care for advanced synchronous or metachronous cancers?

Auteurs : Kourie HR, Awada A
Année : 2015
Journal : Future Oncol
Volume : 11
Pages : 3053-5

Of art and science: is personalized medicine getting personal enough?

Auteurs : Hendlisz A
Année : 2015
Journal : Curr Opin Oncol
Volume : 27(4)
Pages : 349-50

RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy.

Auteurs : Azim HA, Peccatori FA, Brohée S, Branstetter D, Loi S, Viale G, Piccart-Gebhart M, Dougall WC, Pruneri G, Sotiriou C
Année : 2015
Journal : Breast Cancer Res
Volume : 17
Pages : 24

Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial.

Auteurs : Sonnenblick A, Brohée S, Fumagalli D, Rothé F, Vincent D, Ignatiadis M, Desmedt C, Salgado R, Sirtaine N, Loi S, Neven P, Loibl S, Denkert C, Joensuu H, Piccart-Gebhart M, Sotiriou C
Année : 2015
Journal : Oncotarget
Volume : 6
Pages : 30306-16

Participation of Italian Cancer Centres of the Alleanza Contro Il Cancro (ACC) in the Organisation of European Cancer Institutes (OECI) Accreditation and Designation program: a successful first national initiative.

Auteurs : Oberst S, Boomsma F, Lombardo C, Docter M, Blaauwgeers H, De Paoli P, de Valeriola D, Paradiso A, Saghatchian M
Année : 2015
Journal : Tumori
Volume : 101 Suppl 1
Pages : 0

Subclonal diversification of primary breast cancer revealed by multiregion sequencing.

Auteurs : Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, Aas T, Alexandrov LB, Larsimont D, Davies H, Li Y, Ju YS, Ramakrishna M, Haugland HK, Lilleng PK, Nik-Zainal S, McLaren S, Butler A, Martin S, Glodzik D, Menzies A, Raine K, Hinton J, Jones D, Mudie LJ, Jiang B, Vincent D, Greene-Colozzi A, Adnet PY, Fatima A, Maetens M, Ignatiadis M, Stratton MR, Sotiriou C, Richardson AL, Lønning PE, Wedge DC, Campbell PJ
Année : 2015
Journal : Nat. Med.
Volume : 21(7)
Pages : 751-9

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.

Auteurs : Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, + collaborators (among others :, Dal Lago L, de Azambuja E, Dabakuyo-Yonli TS
Année : 2015
Journal : Ann Oncol
Volume : 26(5)
Pages : 873-879.

Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility.

Auteurs : Ignatiadis M, Lee M, Jeffrey SS
Année : 2015
Journal : Clin Cancer Res
Volume : 21
Pages : 4786-800

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.

Auteurs : Salgado R, Denkert C, Campbell C, Savas P, Nucifero P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J, Piccart-Gebhart M, Michiels S, Bradbury I, Sotiriou C, Loi S
Année : 2015
Journal : JAMA Oncol
Volume : 1(4)
Pages : 448-54

Adult onset asynchronous multifocal eosinophilic granuloma of bone: an 11-year follow-up.

Auteurs : Dallaudière B, Kerger J, Malghem J, Galant C, Lecouvet FE
Année : 2015
Journal : Acta Radiol Open
Volume : 4(2)
Pages : 2047981614552217

Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome.

Auteurs : Fumagalli D, Gacquer D, Rothé F, Lefort A, Libert F, Brown D, Kheddoumi N, Shlien A, Konopka T, Salgado R, Larsimont D, Polyak K, Willard-Gallo K, Desmedt C, Piccart-Gebhart M, Abramowicz M, Campbell PJ, Sotiriou C, Detours V
Année : 2015
Journal : Cell Rep
Volume : 13
Pages : 277-89

Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.

Auteurs : Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman PA, Awada A
Année : 2015
Journal : Breast Cancer Res. Treat.
Volume : 149(1)
Pages : 313

Radioembolisation and portal vein embolization before resection of large hepatocellular carcinoma.

Auteurs : Bouazza F, Poncelet A, Garcia CA, Delatte P, Engelholm JL, Gomez Galdon M, Deleporte A, Hendlisz A, Vanderlinden B, Flamen P, Donckier V
Année : 2015
Journal : World J Gastroenterol
Volume : 21
Pages : 9666-70

Evolving paradigms in multifocal breast cancer.

Auteurs : Salgado R, Aftimos P, Sotiriou C, Desmedt C
Année : 2015
Journal : Semin. Cancer Biol.
Volume : 31C
Pages : 111-118

Adjuvant systemic therapy in breast cancer: quo vadis?

Auteurs : Sonnenblick A, Piccart-Gebhart M
Année : 2015
Journal : Ann Oncol
Volume : 26(8)
Pages : 1629-34

Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.

Auteurs : Nuciforo PG, Aura C, Holmes E, Prudkin L, Jimenez J, Martinez P, Ameels H, de la Peña L, Ellis C, Eidtmann H, Piccart-Gebhart M, Scaltriti M, Baselga J
Année : 2015
Journal : Ann Oncol
Volume : 26
Pages : 1494-500

Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?

Auteurs : Pagani O, Ruggeri M, Manunta S, Saunders C, Peccatori F, Cardoso F, Kaufman B, Paluch-Shimon S, Gewefel H, Gallerani E, Abulkhair O, Pistilli B, Warner E, Saloustros E, Perey L, Zaman K, Rabaglio M, Gelber S, Gelber Rd, Godhirsch A, Korde L, Azim HA, Partridge AH
Année : 2015
Journal : Breast
Volume : 24(3)
Pages : 201-7

Cardiac assessment of early breast cancer patients 18years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.

Auteurs : de Azambuja E, Ameye L, Diaz M, Vandenbossche S, Aftimos P, Hernández SB, Shih-Li C, Delhaye F, Focan C, Cornez N, Vindevoghel A, Beauduin M, Lemort M, Paesmans M, Suter T, Piccart-Gebhart M
Année : 2015
Journal : Eur J Cancer
Volume : 51
Pages : 2517-24